You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.
The company hopes to develop saliva-based RNA assays for concussion, Parkinson's disease and autism using biomarkers discovered by its two academic partners.
Newly launched aggregator Seqster will help Boston University researchers collect data from EHRs, wearables, and gene tests to identify concussion biomarkers.
The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
Researchers have developed a spit-based miRNA test to gauge concussion duration in children, NPR reports.
Researchers and companies move to develop blood-based tests for concussion, according to Scientific American.
The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.
Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.